Navigation Links
BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
Date:2/16/2012

RALEIGH, N.C. and CHADDS FORD, Pa., Feb. 16, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance of BDSI's patent application (No. 13/184306) that, once formally granted, will extend the exclusivity of the BioErodible MucoAdhesive (BEMA) drug delivery technology for BEMA Buprenorphine and BEMA Buprenorphine/Naloxone from 2020 to 2027. 

A Notice of Allowance is issued when the USPTO has determined to grant a patent.  Once the issue fee is paid, the final granting of the patent takes place, typically within a few months.

As a part of BDSI's recently signed BEMA Buprenorphine licensing and development agreement with Endo Pharmaceuticals (Nasdaq: ENDP), BDSI is entitled to a milestone payment in the amount of $15 million upon the final granting of this patent. 

"We are very pleased by the allowance of this patent application by the USPTO, that will not only provide non-dilutive capital to BDSI in the next couple months, but importantly extends the period of exclusivity, and thus the potential for a longer royalty stream, for BEMA Buprenorphine in its use for treating chronic pain following FDA approval and commercial launch," stated Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI.  "It is an added benefit that this patent upon granting will afford similar protection to BEMA Buprenorphine/Naloxone for the treatment of opioid dependence."

"Endo is committed to serving as an integrated solutions provider for the development and commercialization of products focused on the management of pain," said Dr. Ivan Gergel, M.D., executive vice president, R&D and chief scientific officer, Endo Pharmaceuticals. "And the allowance of t
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioDelivery Sciences Announces Results from Phase 3 Efficacy Study for BEMA Buprenorphine in Chronic Pain
2. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
3. BioCrossroads Commemorates Decade of Collaboration, Success for Indiana Life Sciences Sector
4. Spherix to Present at the LHA Life Sciences & Medical Technologies Virtual Conference on February 16
5. Ambit Biosciences to Present at Two Upcoming Investor Conferences
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
8. Lend Lease Announces the Appointment of Tom Chapman as Director Operations for the Life Sciences Group in the Atlantic Region
9. Excel Life Sciences Joins DATATRAKs Connect Partner Program
10. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
11. Elsevier Acquires QUOSA, Provider of Life Sciences Content Management and Workflow Productivity Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 A study has ... on the Formula 1 track could help to tackle the ... Technologies (MAT), Stowhealth (a GP surgery based in Stowmarket) and ... provider Simplyhealth. Telemetry technology, which is inspired by ...
(Date:1/15/2014)... 15, 2014 Two champions of science, ... sponsorship of an annual competition for middle and high ... to, innovative STEM study. The competition presents students with ... of Engineering Aptitude, Mathematics, and Sciences is a ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to ... Science organizations who need document translations. Clients will now ... documents in advance with a selection of nearly 50 life ... a critical factor in clinical and scientific fields, and decrease ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... (NASDAQ: SQNM ), a life sciences company ... new publication from the large Women & Infants multi-center ... (Sequenom CMM) MaterniT21 PLUS laboratory-developed test (LDT) ... Prenatal Diagnosis . Along with this week,s publication, the ...
... May 16, 2012  Sigma-Aldrich announced today that it has ... will mature on May 10, 2017.  The new facility ... scheduled to mature on December 11, 2012.  The $600 ... paper program and be used for general corporate purposes. ...
... Reportlinker.com announces that a new market research ...   Global Anti-Microbial Coatings ...   This report analyzes the US ... the following End-Use Segments: Indoor Air Quality, and ...
Cached Biology Technology:Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 2Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 3Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 4Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 5Global Anti-Microbial Coatings Industry 2Global Anti-Microbial Coatings Industry 3Global Anti-Microbial Coatings Industry 4Global Anti-Microbial Coatings Industry 5Global Anti-Microbial Coatings Industry 6Global Anti-Microbial Coatings Industry 7Global Anti-Microbial Coatings Industry 8Global Anti-Microbial Coatings Industry 9Global Anti-Microbial Coatings Industry 10Global Anti-Microbial Coatings Industry 11Global Anti-Microbial Coatings Industry 12Global Anti-Microbial Coatings Industry 13
(Date:4/17/2014)... stem cell therapies to cure a variety of diseases ... based on cell surface markers. Researchers from the Finnish ... highly expressed in a type of stem cells derived ... an article in BioResearch Open Access , a ... article is available free on the BioResearch ...
(Date:4/17/2014)... developed at Sandia National Laboratories and recently licensed to ... cheaper. , Bacillus anthracis , the bacteria ... over the world and can cause serious, and often ... can survive in harsh conditions for decades. In humans, ... skin contact, inhalation of spores or eating contaminated meat. ...
(Date:4/17/2014)... produce hydrogen sulfide in order to properly multiply and ... the Center for Craniofacial Molecular Biology at the Herman ... Shi, principal investigator on the project, said the presence ... flow of calcium ions. The essential ions activate a ... the creation of new bone tissue, and keeps the ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... congenital valvular heart disease. Now, in patients with this ... the Netherlands, the University of Newcastle, UK and the ... identified mutations in a gene which plays an important ... hope that these findings will lead to faster diagnosis ...
... Jan. 10, 2011 Aware, Inc. (Nasdaq: AWRE ... telecommunications and biometrics industries, today announced that on January 5, ... Jr. and John S. Stafford, III to the Aware Board ... a Class III Director and will serve on the Board,s ...
... Bio-Technology Group Co., Inc. (OTC Bulletin Board: ... leading developer, manufacturer and marketer of Traditional Chinese ... other health and nutritional products in the People,s ... its private placement offering for aggregate gross proceeds ...
Cached Biology News:Researchers link gene mutations to Ebstein's anomaly 2Aware Announces Appointment of New Directors 2Aware Announces Appointment of New Directors 3Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 2Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 3
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
NuParaffin Kit Application: Flow Cytometry Reactivity: Human...
Immunofixation Gel Kit, requires IF100 Reactivity: Human Applications: Immunofixation ...
...
Biology Products: